Denver, CO, April 8, 2026: AOA Dx announces the appointment of Cory Bystrom as Senior Director, Biomarker & Analytical Development. Cory brings deep expertise in liquid chromatography–mass spectrometry (LC-MS) diagnostics and will lead the advancement of AOA Dx’s platform from early development through clinical validation and regulatory submission.
Cory is recognized as a global expert who has successfully translated LC-MS diagnostics from discovery through clinical deployment. His experience spans discovery research to regulated assay development across biopharma and diagnostic sectors, including programs that have advanced to commercial launch. With over 20 years of experience across Quest Diagnostics, Cleveland HeartLab, Cedars-Sinai, and Ultragenyx, he has built a strong foundation in clinical translation of novel diagnostics.
In his new role, Cory will lead the development and scaling of AOA Dx’s analytical capabilities, ensuring robust, high-quality assay performance to support clinical operations. He will focus on driving the company’s LC-MS platform through the analytical rigor required for CLIA operations, laboratory-developed test (LDT) launch, and future FDA submissions.
“I’m excited to join AOA Dx at such a pivotal stage,” said Bystrom. “The team has built a strong scientific foundation, and I look forward to advancing the platform into clinical and regulatory milestones that will ultimately enable broader patient access.”
“Cory’s track record of advancing mass spectrometry-based diagnostics from concept to clinic is exceptional,” said Oriana Papin-Zoghbi, CEO of AOA Dx. “His leadership enhances our ability to convert scientific discovery into clinically validated, clinic-ready solutions that can improve patient outcomes.”
Ovarian cancer remains one of the most lethal gynecologic malignancies, largely because most women are diagnosed at advanced stages when treatment options are limited and survival rates fall dramatically. With no early detection test available today, women presenting to their provider with vague abdominal symptoms are often-dismissed and face a diagnostic odyssey that costs critical time. AOA Dx is closing that gap — moving from discovery to the clinic with a validated, multi-omic approach designed to give women and their physicians answers when it matters most.